Insmed (INSM) reported preliminary 2024 revenue results for its drug Arikayce and issued 2025 revenue guidance. Read more ...

Shares of Dyne Therapeutics, Inc. (Nasdaq: DYN) plummeted 25% as the biotechnology firm reported early trial data for its experimental therapy for myotonic dystrophy type 1 (DM1), a genetic disorder ...

From undiagnosed genetic conditions to cancer and muscular dystrophy, three parents share how they turned pain into ...

In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Solid Biosciences (SLDB – Research Report), with a ...

In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Solid Biosciences (SLDB – Research Report), with a price ...

Equities researchers at Zacks Research cut their Q1 2025 earnings estimates for shares of Sarepta Therapeutics in a research ...

Geode Capital Management LLC grew its position in Benitec Biopharma Inc. (NASDAQ:BNTC – Free Report) by 31.3% during the 3rd quarter, according to the company in its most recent disclosure with the ...

Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --2025 Global ARIKAYCE Revenues Expected to be Between $405 Million ...

Dyne Therapeutics (NASDAQ:DYN) reported clinical data from its ongoing Phase 1/2 trial of DYNE-101 in patients with myotonic dystrophy type 1. Shares down about 22% in early trade. DYNE-101 continued ...

Saad Z. Usmani, MD, MBA, FACP, discusses how the definition of the transplant-ineligible population for multiple myeloma is evolving while also addressing the challenges of standardizing minimal ...